Akahane Kenji, Ojima Kazuma, Yokoyama Ayaka, Inoue Toshihiro, Kiguchi Sumiyoshi, Tatemichi Satoshi, Takeda Hiroo, Imai Yohsuke
Pharmacology Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., Azumino, Nagano, Japan.
Clin Exp Pharmacol Physiol. 2017 Dec;44(12):1263-1271. doi: 10.1111/1440-1681.12823. Epub 2017 Sep 5.
We examined the effects of combining the rapid insulin secretagogue, mitiglinide, with various oral hypoglycaemic drugs including biguanides, pioglitazone, α-glucosidase inhibitors, and sodium-glucose co-transporter 2 inhibitors in a rat model of type 2 diabetes. The oral glucose tolerance test (OGTT) using glucose, sucrose, or a liquid meal was used to compare the effects of mitiglinide with those of the four oral hypoglycaemic drugs and examine their combined effects on blood glucose levels and insulin secretion in the rat model. The combination of mitiglinide with other oral hypoglycaemic drugs suppressed the plasma glucose levels more than either agent did alone. Furthermore, the combination of these agents decreased insulin secretion more than mitiglinide did alone. These results indicate that mitiglinide is suitable for use in combination with other hypoglycaemic drugs because it inhibits postprandial hyperglycaemia by rapidly stimulating insulin secretion.
我们在2型糖尿病大鼠模型中研究了速效胰岛素促分泌剂米格列奈与各种口服降糖药(包括双胍类、吡格列酮、α-葡萄糖苷酶抑制剂和钠-葡萄糖协同转运蛋白2抑制剂)联合使用的效果。使用葡萄糖、蔗糖或流食进行口服葡萄糖耐量试验(OGTT),以比较米格列奈与四种口服降糖药的效果,并研究它们对大鼠模型血糖水平和胰岛素分泌的联合作用。米格列奈与其他口服降糖药联合使用比单独使用任何一种药物更能抑制血糖水平。此外,这些药物联合使用比单独使用米格列奈更能降低胰岛素分泌。这些结果表明,米格列奈适用于与其他降糖药联合使用,因为它通过快速刺激胰岛素分泌来抑制餐后高血糖。